PLT Health Solutions announced the results of two pre-clinical trials, and one yet-to-be-published clinical trial that offer fresh insights into the mechanisms of action behind its Slendacor Weight Management Complex ingredient’s weight management benefits.
PLT Health Solutions (Morristown, NJ) announced the results of two pre-clinical trials, and one yet-to-be-published clinical trial that offer fresh insights into the mechanisms of action behind its Slendacor Weight Management Complex ingredient’s weight management benefits. Slendacor is a patented combination of turmeric (Curcuma longa), drumstick leaves (Moringa oleifera), and curry leaves (Murraya koenigii).
“Slendacor was introduced in 2017, and its fast-acting benefits, clean label formulation, and robust portfolio of scientific support helped it quickly become a market leading dietary supplement weight management ingredient around the world – powering top brands in the United States, Australia, Europe, and Brazil,” said Seth Flowerman, president and CEO of PLT, in a press release. “These new studies further enhance the range of claims that our customers will be able to communicate and demonstrate how Slendacor promotes overall human health – while helping people manage their weight.”
In the first pre-clinical trial1, published in Lipids in Health and Disease, seven rats were fed a regular diet and 21 rats were fed a high fat diet and randomized to receive either a daily oral gavage of 0.5% Carboxymethylcellulose Sodium, 100 mg/kg or 250 mg/kg of Slendacor from day 29 to day 56 of the study. Results showed that rats at both dosage levels experienced significantly increased resting energy expenditure, while the rats receiving the highest dosage showed significant upregulation of uncoupling protein-1 expression. Ultimately, supplementation significantly reduced body weight gain, fat mass, fat cell size, liver weight, and hepatic triglycerides, as well as serum triglyceride, total cholesterol, glucose, leptin, and fat cell markers, compared to gavage and high fat diet.
In the second pre-clinical trial2, published in Evidence-Based Complementary and Alternative Medicine, 20 mice were randomly divided, based on body weight, into four groups: normal chow diet, high fat diet, high fat diet with 250 mg/kg of Slendacor, and high fat diet with 500 mg/kg of Slendacor. After 13 weeks of supplementation, results showed that Slendacor at each dosage level suppressed body weight gain and lowered whole-body fat in obese mice. Supplementation at each dosage level also significantly decreased the expression level of adipogenic and lipogenic markers and notable increases in the production level of thermogenetic and lipolytic proteins.
According to PLT, these two pre-clinical trials reveal a dual mode of action for Slendacor, via controlling fat reserves (the modulation of adipogenesis and lipolysis), and by managing energy expenditure (increasing thermogenesis). In the human clinical study awaiting publication, supplementation with Slendacor increased resting energy expenditure by 15.2% after seven days. Calorie burning also significantly increased compared to baseline.
“Our new data on lipolysis shows that Slendacor is not just breaking fat down but increasing the metabolism of that fat and changing the metabolic activity of those fat cells. It is burning fat rather than sending it to energy reserves,” said Jeremy Appleton, ND,director of medical and scientific affairs for PLT. “Healthy weight management has never been solely about shedding pounds. As important as weight loss is to many consumers, we know that healthy and sustainable changes to body weight must involve supporting other related systems, like cardiovascular and metabolic health. These new studies help us understand Slendacor as an integral part of a holistic health management program, one that includes body weight, but in the greater context of cardiometabolic health.”